Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 2/20 | 0.60 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.60 |
| ▸ | RELA | Q04206 | 1/20 | 0.60 |
| ▸ | CETP | P11597 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.33 |
| ▸ | TUBB | P07437 | 1/20 | 0.33 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.33 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.33 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.33 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.33 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.33 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.33 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.33 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.33 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.33 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.33 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Myricanone SCHEMBL29904784 | 1.00 | NFKB1 (0.60) | NFKB1NFKB2RELACETPCYP1A2 | |
| SCHEMBL18649496 | 0.89 | NFKB1 (0.46) | NFKB1NFKB2RELACETPMAOB | |
| SCHEMBL21693012 | 0.85 | NFKB1 (0.53) | NFKB1NFKB2RELACETPMAOB | |
| SCHEMBL21693008 | 0.83 | NFKB1 (0.48) | NFKB1NFKB2RELACETPKDM4E | |
| SCHEMBL16488707 | 0.81 | NFKB1 (0.40) | NFKB1NFKB2RELACETP | |
| SCHEMBL16488711 | 0.81 | NFKB1 (0.40) | NFKB1NFKB2RELACETP | |
| SCHEMBL15113092 | 0.81 | NFKB1 (0.43) | NFKB1NFKB2RELACETPCYP1A2 | |
| SCHEMBL21693006 | 0.81 | NFKB1 (0.43) | NFKB1NFKB2RELACETPCYP1A2 | |
| SCHEMBL433314 | 0.81 | NFKB1 (0.43) | NFKB1NFKB2RELACETPCYP1A2 | |
| SCHEMBL21692990 | 0.80 | NFKB1 (0.40) | NFKB1NFKB2RELACETPCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240315965-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2024-09-26 | — | — | US | claimed |
| WO-2022182527-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2022-09-01 | — | — | WO | claimed |
| US-9206103-B2 | Materials and methods for reduction of protein tau and treatment of neurodegenerative diseases | UNIVERSITY OF SOUTH FLORIDA (US) | 2015-12-08 | — | — | US | claimed |
| US-20150072029-A1 | MATERIALS AND METHODS FOR REDUCTION OF PROTEIN TAU AND TREATMENT OF NEURODEGENERATIVE DISEASES | UNIV SOUTH FLORIDA (US) | 2015-03-12 | — | — | US | claimed |
| US-20130184353-A1 | MATERIALS AND METHODS FOR REDUCTION OF PROTEIN TAU AND TREATMENT OF NEURODEGENERATIVE DISEASES | UNIVERSITY OF SOUTH FLORIDA (US) | 2013-07-18 | — | — | US | claimed |
| WO-2012012798-A2 | MATERIALS AND METHODS FOR REDUCTION OF PROTEIN TAU AND TREATMENT OF NEURODEGENERATIVE DISEASES | UNIVERSITY OF SOUTH FLORIDA (US) | 2012-01-26 | — | — | WO | claimed |
| EP-1569628-B1 | NOVEL USE OF LYCOPENE FOR THE TREATMENT OF DISEASES ASSOCIATED WITH ANDROGEN SIGNALLING | DSM IP ASSETS BV (NL) | 2009-07-22 | — | — | EP | claimed |
| US-20060069151-A1 | Novel use of lycopene | DSM IP ASSETS B.V. (NL) | 2006-03-30 | — | — | US | claimed |
| EP-1569628-A1 | NOVEL USE OF LYCOPENE | DSM IP Assets B.V. (NL) | 2005-09-07 | — | — | EP | claimed |
| WO-2004052351-A1 | NOVEL USE OF LYCOPENE | DSM IP ASSETS B.V. (CH) | 2004-06-24 | — | — | WO | claimed |
| US-12568985-B2 | Milkfat or butterfat formulations | Savor Foods Limited (US) | 2026-03-10 | — | — | US | disclosed |
| EP-4658082-A2 | MILKFAT OR BUTTERFAT FORMULATIONS | Savor Foods Limited (US) | 2025-12-10 | — | — | EP | disclosed |
| US-20250161394-A1 | Compositions Comprising Kavalactones | NATURAL EXTRACTION SYS LLC (US) | 2025-05-22 | — | — | US | disclosed |
| CN-118987216-A | Use of endoplasmic reticulum stress inhibitor in preparation of medicine for eliminating or relieving liver toxicity caused by pezopanib | 杭州颐柏健康管理有限公司 | 2024-11-22 | — | — | CN | disclosed |
| EP-3756660-B1 | MEDICAMENT HAVING ANTI-INFLAMMATORY BOWEL DISEASE FUNCTION, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SUZHOU PHARMAVAN CO LTD (CN) | 2024-11-13 | — | — | EP | disclosed |
| EP-1494993-A2 | NOVEL CURCUMIN ANALOGUES AND USES THEREOF | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2005-01-12 | — | — | EP | disclosed |
| US-6790979-B2 | USE AS ANTITUMOR AGENTS, PARTICULARLY FOR THE TREATMENT OF CANCERS SUCH AS COLON, SKIN AND PROSTATE CANCER AND TO INDUCE ANDROGEN RECEPTOR ANTAGONIST ACTIVITY IN SUBJECT WITH ANDROGEN-RELATED AFFLICTION | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2004-09-14 | — | — | US | disclosed |
| WO-2004052351-A1 | NOVEL USE OF LYCOPENE | DSM IP ASSETS B.V. (CH) | 2004-06-24 | — | — | WO | disclosed |
| WO-2003088927-A2 | NOVEL CURCUMIN ANALOGUES AND USES THEREOF | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2003-10-30 | — | — | WO | disclosed |
| US-20030203933-A1 | Novel curcumin analogues and uses thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130184353-A1 | MATERIALS AND METHODS FOR REDUCTION OF PROTEIN TAU AND TREATMENT OF NEURODEGENERATIVE DISEASES | MAPT, APP, BACE1 | NFKB1 2934/4885NFKB2 2989/4885RELA 2588/4885 |
| US-20150072029-A1 | MATERIALS AND METHODS FOR REDUCTION OF PROTEIN TAU AND TREATMENT OF NEURODEGENERATIVE DISEASES | MAPT, APP, BACE1 | NFKB1 2934/4885NFKB2 2989/4885RELA 2588/4885 |
| US-20030203933-A1 | Novel curcumin analogues and uses thereof | AR, NR5A1, BRDT | NFKB1 1410/4885NFKB2 1001/4885RELA 1044/4885 |
| US-12568985-B2 | Milkfat or butterfat formulations | FABP4, DGAT2, LIPC | NFKB1 4371/4885NFKB2 3547/4885RELA 2983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.